Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

Phase 2

Terminated

Conditions: Diabetes Mellitus

Interventions: Drug: TAK-379
Drug: Placebo
Drug: Pioglitazone

First Posted Date: 2008-07-28

Last Posted Date: 2016-06-22

Lead Sponsor: Takeda

Target Recruit Count: 323

Registration Number: NCT00722917

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine

First Posted Date: 2008-07-02

Last Posted Date: 2013-12-13

Lead Sponsor: Takeda

Target Recruit Count: 836

Registration Number: NCT00707980

Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Alogliptin
Drug: Glipizide

First Posted Date: 2008-07-02

Last Posted Date: 2013-05-24

Lead Sponsor: Takeda

Target Recruit Count: 441

Registration Number: NCT00707993

Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

Phase 4

Completed

Conditions: Bone Metabolism

Interventions: Drug: Placebo
Drug: Pioglitazone

First Posted Date: 2008-07-02

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 156

Registration Number: NCT00708175

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Azilsartan medoxomil and olmesartan
Drug: Placebo
Drug: Olmesartan

First Posted Date: 2008-06-12

Last Posted Date: 2011-07-29

Lead Sponsor: Takeda

Target Recruit Count: 1275

Registration Number: NCT00696241

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Azilsartan medoxomil
Drug: Placebo
Drug: Olmesartan
Drug: Valsartan

First Posted Date: 2008-06-12

Last Posted Date: 2011-04-19

Lead Sponsor: Takeda

Target Recruit Count: 1291

Registration Number: NCT00696436

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Azilsartan medoxomil with or without add-on chlorthalidone
Drug: Azilsartan medoxomil with or without add-on hydrochlorothiazide

First Posted Date: 2008-06-12

Last Posted Date: 2011-04-19

Lead Sponsor: Takeda

Target Recruit Count: 669

Registration Number: NCT00695955

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
Drug: Placebo
Drug: Azilsartan medoxomil

First Posted Date: 2008-06-12

Last Posted Date: 2012-01-04

Lead Sponsor: Takeda

Target Recruit Count: 418

Registration Number: NCT00696384

Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin

Phase 2

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Pioglitazone

First Posted Date: 2008-05-13

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 29

Registration Number: NCT00676260

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

Phase 2

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: TAK-442
Drug: Placebo

First Posted Date: 2008-05-13

Last Posted Date: 2016-04-13

Lead Sponsor: Takeda

Target Recruit Count: 2753

Registration Number: NCT00677053

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy